Re:Clinical Failure Rates over the Decades: Yikes
by mft_ on Sunday July 26, 2026 @06:06AM
(#49056469)
> it is generally not a career advancement move for a project manager to kill the drug candidate they oversee.
You're grossly oversimplifying the process. The decision to "kill" a drug is huge, especially if it's already in the clinic (per the article). That decision will be taken by a large group of people, not an individual - and certainly not a "project manager".
Re:Clinical Failure Rates over the Decades: Yikes
by rwmj on Sunday July 26, 2026 @04:45AM
(#49056023)
Sure, but Pharma A is full of career managers who never kill drugs under development and Upstart B relentlessly culls drugs that don't work early on. Upstart B's failure rate at the final stages is under 50% so they develop 5 times as many drugs, beating the existing company, and indeed all other drug companies.
Since this isn't happening, it seems this might not be the explanation.
Re:Clinical Failure Rates over the Decades: Yikes
by ozim on Sunday July 26, 2026 @05:39AM
(#49056330)
For me it seems this simplification falls flat right away when you take into account budget constraints.
It is not software development where you can start a project every month see how it goes and drop it or pivot.
I guess they use a lot of computer aided models before they even start serious parts but I believe this discussion is not about failure rates on that stage because then it would be 99%
Re:Clinical Failure Rates over the Decades: Yikes
by logicchains on Sunday July 26, 2026 @05:04AM
(#49056123)
The human body is an extremely complex system. Simulating it completely accuracy would require a computer many orders of magnitude more powerful than anything currently existing, so the only way to know if a treatment doesn't produce any unexpected side effect is years of empirical testing, because such things can take years to manifest. Fundamentally the problem space contains inescapable complexity; it's not the fault of pharma firms.
As with many cases where companies make seemingly bad decisions, I think a lot of the explanation lies in system dynamics. Think about the incentive structure inside large pharma companies - it is generally not a career advancement move for a project manager to kill the drug candidate they oversee. It is career advancing to get it approved for the next stage. What could possibly go wrong in this world?